UNSPSC 51171603: Docusate potassium

This classification denotes a stool softener with the molecular formula C20H37O7S.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CIK9F54ZHR, chemically known as potassium 1,4-bis(2-ethylhexyl) sulfosuccinate but generally known as docusate potassium, which bears US NIH Compound Identifier 24097. European Medicines Agency schedules Docusate potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01807MIG. As of Q4 2014, DOCUSATE POTASSIUM remains the US FDA Preferred Term for this commodity.

Docusate potassium bears US NLM identifiers UMLS ID C0282141 and NCI Concept Code C76971. SMILES: CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)[O-].[K+].

UNSPSC 51171603 Docusate potassium is a Commodity code that, based on recent state and local solicitations, covers individual pharmaceutical products procured for use in correctional, public health, and multi-state cooperative purchasing programs. State and local governments buying under this code include county correction departments, state health and human services agencies, and cooperative purchasing alliances spanning multiple states and localities. The scope encompasses supply and distribution of pharmaceutical products (both branded and generic formulations) through authorized wholesaler networks, with vendors required to maintain FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and appropriate insurance coverage. Contracts typically specify pricing by National Drug Code, packaging configurations, strength and dosage form, and distribution through established pharmaceutical supply chains.

Collin County Community Supervision and Corrections Department (Texas) posted RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services, due July 23, 2026, with an estimated contract value of $600,000 over two years plus optional renewals—though this opportunity focuses primarily on testing services rather than pharmaceutical supply. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance and capability. The Texas Health and Human Services Commission posted RFI HHS0017013 in March 2026 to explore direct-to-manufacturer prescription programs, signaling exploratory procurement planning rather than immediate opportunity. Recent activity concentrates in Texas and the upper Midwest, with MMCAP representing a significant multi-jurisdiction cooperative vehicle.